TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus

Increased type I interferon (IFN-I) production and IFN-stimulated gene (ISG) expression are linked to the pathogenesis of systemic lupus erythematosus (SLE). Although the mechanisms responsible for dysregulated IFN-I production in SLE remain unclear, autoantibody-mediated uptake of endogenous nuclei...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of experimental medicine Vol. 205; no. 13; pp. 2995 - 3006
Main Authors: Lee, Pui Y., Kumagai, Yutaro, Li, Yi, Takeuchi, Osamu, Yoshida, Hideo, Weinstein, Jason, Kellner, Erinn S., Nacionales, Dina, Barker, Tolga, Kelly-Scumpia, Kindra, van Rooijen, Nico, Kumar, Himanshu, Kawai, Taro, Satoh, Minoru, Akira, Shizuo, Reeves, Westley H.
Format: Journal Article
Language:English
Published: The Rockefeller University Press 22-12-2008
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased type I interferon (IFN-I) production and IFN-stimulated gene (ISG) expression are linked to the pathogenesis of systemic lupus erythematosus (SLE). Although the mechanisms responsible for dysregulated IFN-I production in SLE remain unclear, autoantibody-mediated uptake of endogenous nucleic acids is thought to play a role. 2,6,10,14-tetramethylpentadecane (TMPD; also known as pristane) induces a lupus-like disease in mice characterized by immune complex nephritis with autoantibodies to DNA and ribonucleoproteins. We recently reported that TMPD also causes increased ISG expression and that the development of the lupus is completely dependent on IFN-I signaling (Nacionales, D.C., K.M. Kelly-Scumpia, P.Y. Lee, J.S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W.H. Reeves. 2007. Arthritis Rheum. 56:3770–3783). We show that TMPD elicits IFN-I production, monocyte recruitment, and autoantibody production exclusively through a Toll-like receptor (TLR) 7– and myeloid differentiation factor 88 (MyD88)–dependent pathway. In vitro studies revealed that TMPD augments the effect of TLR7 ligands but does not directly activate TLR7 itself. The effects of TMPD were amplified by the Y-linked autoimmune acceleration cluster, which carries a duplication of the TLR7 gene. In contrast, deficiency of Fcγ receptors (FcγRs) did not affect the production of IFN-I. Collectively, the data demonstrate that TMPD-stimulated IFN-I production requires TLR7/MyD88 signaling and is independent of autoantibody-mediated uptake of ribonucleoproteins by FcγRs.
Bibliography:CORRESPONDENCE Pui Y. Lee: puilee05@ufl.edu
Abbreviations used: ago2, argonaute 2; ANA, antinuclear antibody; clo-lip, clodronate-containing liposomes; ds, double stranded; IC, immune complex; IFN-I, type I IFN; IPS-1, IFN-b promoter stimulator 1; IRF, IFN regulatory factor; ISG, IFN-stimulated gene; MCP, monocyte chemoattractant protein; Mda5, melanoma differentiation-associated gene 5; MFI, mean fluorescence intensity; Mx1, myxoma response protein 1; MyD88, myeloid differentiation factor 88; PDC, plasmacytoid DC; PEC, peritoneal exudate cell; RIG-I, retinoic acid–inducible gene I; RT-PCR, real-time quantitative PCR; SLE, systemic lupus erythematosus; snRNP, small nuclear ribonucleoprotein; ss, single stranded; TBK-1, TANK-binding kinase 1; TLR, Toll-like receptor; TMPD, 2,6,10,14-tetramethylpentadecane; TRIF, Toll/IL-1 receptor domain–containing adaptor inducing IFN-b; Yaa, Y-linked autoimmune accelerating.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20080462